Evolus

Evolus is the commercialization company behind Jeuveau in the United States and Nuceiva in several markets outside the United States. The product originates with Daewoong Pharmaceutical, which developed and manufactures the Nabota product family.

That division of roles is central to the company graph: Daewoong supplies the product and manufacturing identity, while Evolus holds important commercialization rights and presents the brand to aesthetic markets. The relationship does not make Nabota, Jeuveau, and Nuceiva one universal regulatory label.

Quick Answers

Question	Short answer
Is Evolus a botulinum toxin manufacturer?	Evolus is best read as a commercialization company for Jeuveau in the United States and Nuceiva in selected international markets. Daewoong is the product-origin and manufacturing node.
Who makes Jeuveau?	Jeuveau is the U.S. brand for a Daewoong-origin prabotulinumtoxinA product commercialized by Evolus.
What is the relationship between Jeuveau and Nuceiva?	Evolus presents Jeuveau as the U.S. name and Nuceiva as the name used outside the United States, but local approvals, labels, and availability remain market-specific.
Is Jeuveau the same as Nabota?	They belong to the same Daewoong-origin product family, but the names should not be treated as a single global label or universal approval.
Does Evolus sell therapeutic botulinum toxin products?	Evolus positions itself around cash-pay aesthetics rather than a broad therapeutic toxin franchise. U.S. Jeuveau labeling is for adult glabellar lines.
Did the Medytox / Allergan dispute prove clinical superiority?	No. The dispute and settlements are market-access and trade-secret history, not evidence that one botulinum toxin product is safer, stronger, longer-lasting, or unit-equivalent.

Reference Card

Field	Reference point
Company	Evolus, Inc.
Base	United States
Website	evolus.com 🔗
Public status	Nasdaq-listed; ticker EOLS 🔗
Core toxin relationship	Commercialization of Jeuveau in the United States and Nuceiva in selected international markets
Product origin and manufacturing	Daewoong Pharmaceutical and its Nabota product family
Main brand node	Jeuveau / Nabota
Market focus	Self-pay aesthetic products rather than a broad therapeutic toxin franchise
U.S. product identity	Jeuveau is prabotulinumtoxinA-xvfs for injection
U.S. label anchor	Temporary improvement in the appearance of moderate-to-severe glabellar lines in adults

Person	Why the relationship matters
David Moatazedi	Evolus Chief Executive Officer, useful for connecting Jeuveau / Nuceiva commercialization to the company’s self-pay aesthetics strategy.

Jeuveau Manufacturer And Daewoong Relationship

Evolus licenses prabotulinumtoxinA-related rights from Daewoong and purchases Jeuveau from the Korean manufacturer. U.S. labeling identifies Jeuveau as prabotulinumtoxinA-xvfs and gives it a product-specific indication, potency assay, preparation, and safety framework.

The manufacturer question therefore has two layers:

Relationship	Company role	Reader caution
Product origin and manufacturing	Daewoong Pharmaceutical	Manufacturing origin does not make every Nabota-family market name share the same label or approved use.
U.S. and selected international commercialization	Evolus	Commercial rights do not make Evolus the physical manufacturer of the Daewoong-origin product family.

Jeuveau, Nuceiva, And Nabota Naming

Jeuveau is the U.S. brand name used by Evolus. Nuceiva is the name Evolus uses outside the United States. Nabota remains the important Daewoong-origin product-family name, especially when following Korean manufacturing, export, and partner relationships.

Those names are connected, but they should not be flattened into one universal regulatory identity. Approval conditions, indications, presentations, adverse-event language, and availability still depend on the local market and the relevant product information.

Legal and Commercial History

Daewoong, Evolus, Medytox, and AbbVie / Allergan were connected through a U.S. International Trade Commission dispute concerning botulinum toxin manufacturing-process trade secrets. Settlement agreements announced in 2021 removed important barriers to Evolus commercialization in its territories.

The dispute and settlements belong to ownership, licensing, and market-access history. They do not establish that Jeuveau, Nabota, Botox, or another toxin product is clinically superior, safer, stronger, longer-lasting, or unit-equivalent.

Market Interpretation

Evolus is a useful example of a commercialization node that is distinct from a manufacturer. A reader following Jeuveau through the graph should be able to identify Evolus as the U.S. commercial company, Daewoong as the product-origin and manufacturing company, and the Jeuveau label as the controlling U.S. regulatory reference.

Evolus also helps explain why company pages should separate toxin products from adjacent aesthetic products. Evolus has expanded beyond a single neurotoxin brand, but Jeuveau / Nuceiva remains the botulinum toxin relationship that makes Evolus relevant to this manufacturer graph.

Label and Comparison Limits

U.S. Jeuveau interpretation should begin with current prescribing information. The label identifies Jeuveau as prabotulinumtoxinA-xvfs and states that its potency units are specific to the product and assay method. Those units should not be compared with or converted into units of Botox, Dysport, Xeomin, Daxxify, Letybo, or another botulinum toxin product.

The Evolus / Daewoong relationship is useful for market structure, but it is not a shortcut for clinical comparison. Product claims need product-specific labels, local approval context, and appropriately sourced evidence.